🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验结果首次挂网Doubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·源无时间·以抓取为准·⟳ 抓取 20:05:01·⚡ 决策 10-15 20:08:19 +3m18s·12.1 天前
ClinicalTrials.gov 挂网 itepekimab（抗IL-33）COPD 三期试验 AERIFY-1（NCT04701983）结果表，但为旧数据例行披露，无新增信息
本次信号是 ClinicalTrials.gov 对已完成三期试验 AERIFY-1 的结果表例行挂网：顶线数据 16 个多月前（2025-05-30）已由两家公司联合发布（AERIFY-1 达标、AERIFY-2 未达标），更早在 2024 年 ERS 及期刊公开；信号正文不含任何新数字，属合规性旧数据披露，无预期差、无可交易 edge。
📄 原文ClinicalTrials.gov · 试验结果首次挂网↗ 原文
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-o…
不做 Regeneron Pharmaceuticals（REGN.US）
旧临床结果的 ClinicalTrials.gov 例行挂网，无新增事实，混合顶线（AERIFY-1 达标/AERIFY-2 失败）已于 2025-05-30 定价，无 edge
不做 Sanofi（SAN.FR）
同上，结果表挂网不构成新催化；itepekimab 对赛诺菲亦无新增边际信息
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
NCT04701983 即 AERIFY-1，itepekimab 前吸烟者 COPD 三期顶线已于 2025 年 5 月明牌（两项试验仅一项达标），此次 ClinicalTrials.gov 结果挂网仅为旧数据的法定表格化披露，对 Regeneron/Sanofi 无增量影响，不做。
消息传播链
- results_posted 仅为旧结果的表格化合规披露，正文只列终点、无新数据，不构成新催化
关键理由
- 无新增利多：数据库挂网内容仅为试验目的，疗效与安全性结论已在 2025-05-30 官方新闻稿与 2024 年期刊/ERS 数据中公开并被定价
主要风险
- 极小概率结果表含未公开亚组或安全性细节，但法定结果披露通常与已发表结果一致，不足以构成新方向
反向证据
- 做多前查反向 · 来源 web · 影响 none
未发现本次挂网附带任何新的获批、申报或超预期数据；混合三期结果后项目前景未变，无做多依据
检索:itepekimab AERIFY 2026 new data approval filing FDA 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认无预期差后直接 AVOID，未以历史涨跌幅度设定任何交易参数
方向:无适用先例：本事件性质为旧临床结果的数据库补录，而非新的临床读出，不应以历史临床数据公布的股价反应来套用
涨幅量级:不适用
形态:无
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`aeridrus itepekimab former smokers exacerbation results posting | itepekimab nct04701983 copd results clinicaltrials.gov | itepekimab 前吸烟者 copd 三期 试验结果 挂网 regeneron sanofi`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表 - web_search 成功 doubao_search · 2,055 ms
豆包搜索结果（原始查询:itepekimab AERIDRUS NCT04701983 COPD results former smokers Regeneron Sanofi；API SearchType:web） - web_search 成功 doubao_search · 1,849 ms
豆包搜索结果（原始查询:itepekimab phase 3 COPD AERIDRUS top-line results 2024 2025 primary endpoint former smokers；API SearchType:web）
原文全文
展开原文 · 1,564 字
Primary Objective:
Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD
Secondary Objectives:
* Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD
* Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD
* Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD
* Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD
Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD
Secondary Objectives:
* Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD
* Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD
* Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD
* Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD
* Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ea0cd7f382· 2026-10-15 20:08 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前